The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Alexion Pharmaceuticals

  • ALXN
  • NASDAQ
  • Consumer Products
  • Latest 163.21
  • Currency US$
  • Change 0.32
  • Percent Change 0.196 %
  • Volume 724,261
  • Fri Jul 11, 2014 04:00 PM EDT NASDAQ data delayed 15 minutes.
  • Open 162.75
  • Previous Close 162.89
  • High 163.75
  • Low 160.89
  • Bidx0 0.0000
  • Askx0 0.0000
  • 52-week High02/25 185.43
  • 52-week Low07/11 95.45
  • Beta 0.61
  • Market Cap 32,287.83M
  • EPS 2.12
  • P/E 76.986
  • Forward P/E 30.28
  • PEG 1.27
  • Annual Dividend 0.0000
  • Yield

News

Financials & Calendars

Income Statement

  • Sales $1,779,020,000
  • Earnings $330,040,000
  • Return on Equity 12.99%

Cash Flow

  • Cash Flow --
  • Cash $528,280,000
  • Current Ratio 5.66

12 months ended Mar 31, 2014.

Trailing 12 month results shown above.
All data is in U.S. dollars.

Balance Sheet

  • Assets $3,379,660,000
  • Liabilities $678,680,000
  • Liabilities-to-Equity Ratio 0.25

Price Ratios

  • Price to Sales 18.15
  • Price to Book 11.95
  • Price to Cash Flow n/a

Event Calendar

Event Last   Next  
Earnings Apr 24 $1.09 Jul 24 $0.99
Surprises Apr 24 29.36% n/a n/a
Dividends n/a n/a n/a n/a
Splits n/a -- n/a n/a

12 months ended Jul 12, 2014.

A look at major corporate events and financial announcements that are coming up.

Company Information

About the Company

Alexion Pharmaceuticals develops pharmaceutical products for the treatment of heart disease, and inflammation, diseases of the immune system and cancer in humans. The company's lead product candidates are genetically altered antibodies that target specific diseases which arise when the human immune system induces undesired inflammation in the human body. These candidates are designed to block components of the human immune system which cause undesired inflammation while allowing beneficial components of the immune system to remain functional.

Related Securities
Symbol Type Latest % Chg

Officers

  • Max Link, Ph.D. Chairman of the Board of Direc
  • Leonard Bell, M.D. Chief Executive Officer;Treasu
  • Company Type: n/a
  • Company Status: n/a
  • Full-time Employees: n/a
  • Incorporation: United States,
    n/a
  • Top 1000 Ranking: Profit: n/a
    Revenue: n/a
    Assets: n/a

Head Office

352 KNOTTER DRIVE
CHESHIRE, CT
06511

Phone: (203)-776-1790
Fax: (203)-2718198


www.alexionpharm.com

Ideas & Discussion

Live Discussion of ALXN on StockTwits